NAFLD Clinical Care Pathway for Veterans

This study is testing a new approach called the NAFLD Clinical Care Pathway (NCCP) to improve how non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) are diagnosed and managed in Veterans. NAFLD is a common liver condition, especially for Veterans with obesity and diabetes. The NCCP intervention uses an "e-trigger" to automatically identify patients at risk, calculates a risk score (FIB-4), and then educates healthcare teams on how to care for these patients. The goal is to ensure more Veterans with NAFLD are diagnosed and receive appropriate care. We are looking for Patient Aligned Care Teams (PACT) at the Michael E. DeBakey VA Medical Center to participate. The study will measure how well NAFLD is diagnosed and risk-stratified at the start and after 6 months.

Study design
This is an interventional study involving 32 Patient Aligned Care Teams (PACTs). The study aims to improve the diagnosis and risk assessment of NAFLD.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be assessed at the start of the study and again after 6 months for NAFLD diagnosis and risk stratification.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06671886

NAFLD Clinical Care Pathway

Recruiting
NAAges 18+InterventionalHealth services
VA Office of Research and Development
~32 participants
Updated 2025-11-14 on ClinicalTrials.gov
What's tested:E-trigger

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
NAFLD Diagnosis and risk stratification
Measured over Baseline, 6 months
NAFLD
MASLD

NCT06671886

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Michael E. DeBakey VA Medical Center, Houston, TX

    Houston, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

  • Hashem B. El-Serag, MD MPH · PRINCIPAL_INVESTIGATOR · Michael E. DeBakey VA Medical Center, Houston, TX

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

The investigators will exclude PACTs with unstable leadership (i.e., pending departure, vacancy) at time of randomization.
PACTs participating in the focus groups in Aim 1 will be excluded in Aim 2 to avoid cross contamination.
PACTs meeting the following criteria will be excluded from randomization in Aim 2:
PACTs who do not treat NAFLD,
PACTs not located at the main hospital,
PACTs with less than 100 visits within 3 months.
  • NAFLD Diagnosis and risk stratificationBaseline, 6 months

    The investigators will use chart reviews to extract unstructured data regarding the primary outcome measure: existence of EHR progress note documenting a new NAFLD diagnosis AND complete risk stratification of NAFLD (i.e., fibrosis). The investigators will use our validated process to guide uniform abstraction and classification.